Hypothesis: Mechanism of irritable bowel syndrome in inflammatory bowel disease

被引:10
|
作者
Uno, Yoshiharu [1 ]
机构
[1] Off Uno Column, 419-2 Yota,Onoe Cho, Kakogawa, Hyogo, Japan
关键词
Inflammatory bowel disease; Irritable bowel syndrome; FODMAP; Mast cell; Ischemia; LOW-FODMAP DIET; IBS-LIKE SYMPTOMS; QUALITY-OF-LIFE; FUNCTIONAL GASTROINTESTINAL SYMPTOMS; ILEAL CROHNS-DISEASE; ULCERATIVE-COLITIS; INTESTINAL PERMEABILITY; HYDROGEN-SULFIDE; BLOOD-FLOW; VISCERAL HYPERSENSITIVITY;
D O I
10.1016/j.mehy.2019.109324
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Functional bowel symptoms can be occurred during remission from inflammatory bowel disease. In this case, a low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diet is effective for the amelioration or prevention of symptoms. However, the reason is not fully explained. This report proposes a hypothesis regarding the entire process in which inflammatory bowel disease with IBS-like symptoms (IBD-IBS) causes symptoms. A detailed process was assumed, starting from high pressure in the lumen and finally to abdominal symptoms. In this process, relationships were linked based on interactions such as ischemia, compliance, pain threshold, visceral hypersensitivity, mast cells, and permeability reported in IBD-IBS. In the process mapping, to understand the relationship between the amount of gas increased by FODMAP and ischemia, the hydrodynamic hypothesis and Ritchie's hypothesis were adapted. Ischemia in dilated intestines due to an increase in gas volume can induce excessive spasms via the mast cells and show the whole process of lowering the pain threshold. From the standpoint of the mechanism of IBD-IBS, the origin trigger may be FODMAP. Therefore, a low-FODMAP diet is recommended to relieve and prevent IBD-IBS symptoms.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] PATHOPHYSIOLOGY OF IRRITABLE BOWEL SYNDROME IN PATIENTS WITH QUIESCENT INFLAMMATORY BOWEL DISEASE
    Oliveira, Diego Brandao
    Carvalho, Naiara Salgado
    Dos Anjos, Gabriele Alves
    Silva, Genoile Oliveira Santana
    [J]. GASTROENTEROLOGY, 2023, 164 (04) : S92 - S92
  • [32] VOLATOMICS IN INFLAMMATORY BOWEL DISEASE AND IRRITABLE BOWEL SYNDROME: PRESENT AND FUTURE
    Van Malderen, Kathleen
    De Man, Joris
    De Winter, Benedicte Y.
    De Schepper, Heiko U.
    Lamote, Kevin
    [J]. GASTROENTEROLOGY, 2020, 158 (06) : S884 - S884
  • [33] Managing symptoms of irritable bowel syndrome in patients with inflammatory bowel disease
    Camilleri, Michael
    [J]. GUT, 2011, 60 (04) : 425 - 428
  • [34] PATHOPHYSIOLOGY OF IRRITABLE BOWEL SYNDROME IN PATIENTS WITH QUIESCENT INFLAMMATORY BOWEL DISEASE
    Oliveira, Diego Brandao
    Carvalho, Naiara Salgado
    dos Anjos, Gabriele Alves
    Silva, Genoile Oliveira Santana
    [J]. INFLAMMATORY BOWEL DISEASES, 2023, 29 : S72 - S72
  • [35] The potential of dextofisopam for treatment of irritable bowel syndrome and inflammatory bowel disease
    Leventer, SM
    Kucharik, RE
    Keogh, JC
    Raudibaugh, K
    Galbraith, K
    Amchin, J
    Keim, KL
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10): : S279 - S279
  • [36] Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease
    Shin, Andrea
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (08) : 1300 - 1301
  • [37] Is irritable bowel syndrome a low-grade inflammatory bowel disease?
    Bercik, P
    Verdu, EF
    Collins, SM
    [J]. GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2005, 34 (02) : 235 - +
  • [38] Symptomatic inflammatory bowel disease in remission - it could be irritable bowel syndrome
    Whorwell, RJ
    [J]. GASTROINTESTINAL INFLAMMATION AND DISTURBED GUT FUNCTION: THE CHALLENGE OF NEW CONCEPTS, 2003, 130 : 53 - 56
  • [39] Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome
    Silberer, H
    Küppers, B
    Mickisch, O
    Baniewicz, W
    Drescher, M
    Traber, L
    Kempf, A
    Schmidt-Gayk, H
    [J]. CLINICAL LABORATORY, 2005, 51 (3-4) : 117 - 126
  • [40] Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome
    Chad K Porter
    Brooks D Cash
    Mark Pimentel
    Akintunde Akinseye
    Mark S Riddle
    [J]. BMC Gastroenterology, 12